News & Press

Abbisko Therapeutics Announces the Appointment of Dr. Jing Ji as Chief Medical Officer

Feb 18,2021
By Abbisko
Back

February 18, 2021, Shanghai – Abbisko Therapeutics Co., Ltd. (“Abbisko” hereafter) a clinical-stage biopharmaceutical company focused on discovering and developing innovative targeted and immuno-oncology therapies, today announced the appointment of Dr. Jing Ji as Chief Medical Officer (CMO).

Dr. Jing Ji has a strong track record and over 20 years of experience in drug development, portfolio management, and other areas of clinical development for innovative medicines. She is a highly experienced leader having held a number of senior executive roles at top tier pharmaceutical and biotech companies.

Prior to joining Abbisko, she was the SVP and Head of Medical and Clinical Development at LianBio, where she successfully led several IND submissions and approvals within a relatively short period of time. Previously, Jing acted as VP and Head of CVRM TA and Head of Clinical Pharmacology and Drug Safety at AstraZeneca China. In this role, she was responsible for China development strategy and execution for AstraZeneca’s CV, renal and metabolic projects and led key academic collaborations with top research centers. Jing’s industry career also included senior positions as Director of Exploratory Medicine at Johnson & Johnson China, Head of Clinical and Scientific Affairs at GSK, as well as Head of Clinical Research Unit of Sanofi-Aventis and MSD. Prior to her career in the industry, Jing began her career as a practicing physician for approximately four years.

Jing received her MD degree in Clinical Medicine, Master’s Degree of Gastroenterology and Hepatology from Shanghai Second Medical School and Fudan University.

“I am thrilled that Jing joined the executive team of the company.” said Dr. Yao-Chang Xu, “Jing’s global clinical development expertise and insights into clinical development are a tremendous addition to our team. We look forward to her guidance to advance our clinical programs and global partnerships. We believe the addition of Jing will further support Abbisko's ambitious goals to accelerate its future growth.”

Jing added, "I am very excited to join Abbisko at this important time in its history and look forward to working with our talented team to build on what we have accomplished, to accelerate our innovative product pipelines and to make a real difference for our patients." 

Tel:(+86) 021-68912098

E-MailL:Public@abbisko.com Bd@abbisko.com

Copyright © 2021 All rights reserved:Abbisko Therapeautics     滬ICP備17056565號-1